SAN CARLOS, Calif., July 11, 2022 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Steven Axon as Chief Executive Officer (CEO) and member of the Board of Directors. Mr. Axon succeeds Peter McWilliams, Ph.D., who will serve as Glycomine’s Chief Business Officer (CBO). Glycomine also announced the appointment of Jacqueline (Jackie) Grant, Ph.D., Principal at Abingworth, and Jason Hafler, Ph.D., Managing Director at Sanofi Ventures, to the company’s Board of Directors.

“We are pleased to welcome Steve to Glycomine’s leadership team as CEO and Jackie and Jason to our Board of Directors. We are grateful for the work that Peter has done to build the company to this stage and look forward to his continued contribution as CBO,” said Christopher Starr, Ph.D., Chairperson of Glycomine’s Board of Directors. “The upcoming Phase 2 clinical study of GLM101 in patients will be an important clinical validation in the development of what we believe will be the first disease-modifying treatment for PMM2-CDG.”

“Glycomine’s GLM101 is a novel and elegant substrate replacement approach with the potential to be a transformative therapy for PMM2-CDG patients and their families,” said Mr. Axon. “The team at Glycomine has achieved a significant milestone in successfully completing the Phase 1 healthy volunteer safety study for GLM101. I am excited to join the company at this pivotal stage of growth as we look to start our first clinical trials in patients and expand our pipeline.”

Prior to joining Glycomine, Mr. Axon served as CEO of Prothelia, a preclinical company focused on the development of treatments for patients with congenital muscular dystrophy. Prior to Prothelia, Mr. Axon was Chief Business Officer at Apellis Pharmaceuticals (Nasdaq: APLS), where he helped to transform it from a small private company to a multi-billion-dollar public company. Prior to Apellis, he was Senior Vice President of Business Development at Merck KGaA. During his 12-year tenure at Merck, he led the acquisition, licensing, and divestiture of many technologies and products. Mr. Axon received a B.Sc and M.Sc. in biomechanical and biomedical engineering from the University of Toronto and his MBA from the International Institute for Management Development in Lausanne, Switzerland.

About GLM101

The company has recently completed dosing in its Phase 1 clinical study of its lead program, GLM101, in healthy volunteers. GLM101 is a mannose-1-phosphate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), previously known as CDG Type Ia. PMM2-CDG is the most prevalent congenital disease of glycosylation but has no FDA-approved treatments.

About Glycomine, Inc.

Glycomine is a clinical-stage biotechnology company developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. The company is based in San Carlos, California and supported by leading international life sciences investors. For more info, visit

Corporate Contact: Peter McWilliams, Ph.D.,

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc.,, +1.858.344.8091